Complement inhibitors are approved by FDA,
C1 inhibitor Berinert, Cinryze, Ruconest and Enjaymo (sutimlimab)
C3 inhibitor Empaveli (pegcetacoplan), SYFOVRE™ (pegcetacoplan injection) ,
C5 inhibitor, Zilbrysq (Zilucoplan), Veopoz (Pozelimab), Izervay (avacincaptad pegol), Soliris (Eculizumab), Ultomiris (ravulizumab) and Tavneos (avacopan)
Factor B inhibitor Fabhalta (Iptacopan)
Factor D inhibitor Voydeya (Danicopan).
| Drug name | Trade Name | Company | Aproval Date | Target | Modality | Indication | |
| CLASSICAL PATHWAY | |||||||
| Cinryze | —— | Takeda Pharmaceuticals | October 2008 | C1r/s; MASPs | Purified native protein | Routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients with Hereditary Angioedema (HAE). | |
| Berinert | —— | CSL Behring | October 2009 | C1r/s; MASPs | Purified native protein | Acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks | |
| Ruconest | —— | Pharming | July 2014 | C1r/s; MASPs | Biologic | Acute attacks in adult and adolescent patients with hereditary angioedema (HAE) | |
| Sutimlimab | Enjaymo | Sanofi | February 2022 | C1s | Ab | Decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD) | |
| ALTERNATIVE PATHWAY/AMPLIFICATION LOOP/COMPLEMENT C3 | |||||||
| Pegcetacoplan | Empaveli | Apellis | May 2021 | C3 | Peptide | Paroxysmal nocturnal hemoglobinuria (PNH) | |
| Pegcetacoplan injection | Syfovre | Apellis | Feb 2023 | C3 | Peptide | Geographic Atrophy | |
| COMPLEMENT C5 | |||||||
| Eculizumab | Soliris | Alexion | May 2007 | C5 | Ab | Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) | |
| Ravulizumab | Ultomiris | Alexion | December, 2018 | C5 | Ab (recycling) | Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS) | |
| Avacincaptad pegol | Izervay | Iveric Bio | Aug 2023 | C5 | Aptamer | Geographic Atrophy | |
| Pozelimab | Veopoz | Regeneron Pharmaceuticals | Aug 2023 | C5 | Ab | CD55-deficient protein-losing enteropathy (PLE) | |
| Zilucoplan | Zilbrysq | UCB, Inc. | Oct 2023 | C5 | Peptide | generalized myasthenia gravis (gMG) | |
| Complement Factor B | |||||||
| Iptacopan | Fabhalta | Novartis | December 2023 | CFB | SM | first oral monotherapy for the treatment of adults with PNH | |
| Complement Factor D | |||||||
| Danicopan | Voydeya | AstraZeneca | April 2024 | CFD | SM | extravascular hemolysis (EVH) in adults with PNH | |
| COMPLEMENT C5a/C5aR1 | |||||||
| Avacopan | Tavneos | Chemocentryx | October 2021 | C5aR1 | SM | Adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis in combination with standard therapy including glucocorticoids | |